US 12,128,114 B2
177Lu-DOTA-HYNIC-iPSMA as a therapeutic radiopharmaceutical targeting prostate-specific membrane antigen
Guillermina Ferro Flores, Estado de México (MX); Blanca Elí Ocampo García, Estado de México (MX); Myrna Alejandra Luna Gutiérrez, Estado de México (MX); Clara Leticia Santos Cuevas, Estado de México (MX); Erika Patricia Azorín Vega, Estado de México (MX); Nallely Patricia Jiménez Mancilla, Estado de México (MX); Tania Hernández Jiménez, Estado de México (MX); and Flor de María Ramírez De La Cruz, Estado de México (MX)
Assigned to INSTITUTO NACIONAL DE INVESTIGACIONES NUCLEARES, Estado de Mexico (MX)
Appl. No. 16/980,252
Filed by INSTITUTO NACIONAL DE INVESTIGACIONES NUCLEARES, Estado de México (MX)
PCT Filed Mar. 7, 2019, PCT No. PCT/MX2019/000025
§ 371(c)(1), (2) Date Sep. 11, 2020,
PCT Pub. No. WO2019/177449, PCT Pub. Date Sep. 19, 2019.
Claims priority of application No. MX/a/2018/003175 (MX), filed on Mar. 14, 2018.
Prior Publication US 2021/0015949 A1, Jan. 21, 2021
Int. Cl. A61K 51/00 (2006.01); A61K 51/04 (2006.01); A61M 36/14 (2006.01)
CPC A61K 51/041 (2013.01) 10 Claims
 
1. A compound comprising a chelator-hydrazinonicotinamide (HYNIC)-prostate specific membrane antigen inhibitor (iPSMA), wherein the chelator is 1,4,7,10-tetraazacyclododecano-N,N′,N″,N″″-tetraacetic acid (DOTA), and wherein the compound has the structure

OG Complex Work Unit Chemistry